Full list of Authors
Leighton R, Åkermark C, Therrien R, Richardson JB, Andersson M, Todman MG, Arden NK.
Full AMA reference
Leighton R., Åkermark C., Therrien R. et al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014; 22: 17-25.
Level-I clinical study: prospective, multi-centre, randomized (1:1), corticosteroid controlled, double-blind.
To compare in a non-inferiority trial the effectiveness and safety of a single intraarticular injection of NASHA® (DUROLANE®) with the commonly used steroid; Methyl Prednisolone Acetate (MPA).
442 patients with knee OA were randomly assigned to a treatment group (221 DUROLANE, 221 MPA). Results were similar between MPA and DUROLANE between 6-18 weeks. However, there was a significant reduction in the responders from week 18-26 in the MPA group which was not observed in the DUROLANE group. In response to a second DUROLANE treatment at 26 weeks, sustained improvements were seen in WOMAC outcomes irrespective of initial treatment. No serious device related AEs were reported.